Stock Updates

How has Vertex Pharmaceuticals Incorporated:(NASDAQ:VRTX) performed recently?

Vertex Pharmaceuticals Incorporated (NASDAQ: VRTX) is a large market cap stock with a market cap of 25301.02. It is in the Biotechnology industry and sector Healthcare, with a current P/E of *TBA, a forward P/E of 32.68 and EPS of -1.13. At a stock price of 101.63 (0.63%) it has a dividend yield of *TBA.

EPS growth for the last five years have been 9.30%, more recently this last year it has grown by 26.50%. The next year growth is going to be about 198.26% and more long-term 53.63% after five years. EPS growth quarter over quarter is 66.40%. Sales growth for the past five years have been 48.40% and sales growth quarter over quarter is 159.80%.

For performance, Vertex Pharmaceuticals Incorporated the past week has seen a gain of 0.99%. For the last month performance for Vertex Pharmaceuticals Incorporated is 5.45%. While the last quarter is 14.22% and half year, 16.39%. Finally for the year, performance is -15.33%.

The 52-week high for Vertex Pharmaceuticals Incorporated, is at -25.80%, and for the 52-week low it comes to a value of 33.90%. The 20-day simple moving average is 9.17% and 5.33% for the 200-day simple moving average.

Volatility for the week is at 2.00%, and for the month it is 2.33%. Vertex Pharmaceuticals Incorporated, has a target price of 110.32.

In terms of debt, long term debt/equity is 0.59, and for total debt/equity Vertex Pharmaceuticals Incorporated has 0.84. The gross margin is 88.00%, while operating margin is -8.70%, the profit margin is -17.70%. The current ratio is 2.3 and the quick ratio is 2.2.

Insider ownership is at 0.30%, with instituitional ownership at 97.90%. Vertex Pharmaceuticals Incorporated has a payout ratio of *TBA. With the total shares outstanding coming to 250.53. The shares float is 246.06, with the float short at 2.30%, with short ratio coming to 4.05.

In terms of returns, the return on assets see Vertex Pharmaceuticals Incorporated, get -11.00%, with its returns on investment at -28.20%. Return on equity is -28.90%. So will the investors see the target price of 110.32, reached soon?

Disclaimer: Remember there is a risk to your investment, this is not a recommendation, nor personal advice, never invest more than you are able too loose.


About the author

Mark Hines

Leave a Comment